Massive Real-World study to see if targeted pills boost survival after lung cancer surgery

NCT ID NCT07593248

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study will follow about 2,000 patients in China who have early-stage lung cancer with a specific gene mutation (EGFR) and have received targeted therapy pills (EGFR-TKIs) after surgery. Researchers will track how long patients live and how long they stay cancer-free over five years. The goal is to see how well these drugs work in everyday medical practice, outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

EGFR-TKI (a type of targeted therapy pill)

What this could lead to

If successful, this study could provide real-world evidence on how well EGFR-TKIs work as an add-on treatment after surgery for early-stage lung cancer, potentially guiding future treatment decisions.

What could go wrong

This is an observational study, not a controlled trial, so results may be influenced by patient differences and cannot prove cause and effect. It only includes patients in China, so findings may not apply globally.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••